Drug Trial Radar · NCT07735533
A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
274
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Aug 2031
Study completion Aug 2031
Sponsor
- Lead sponsor
- Umoja BiopharmaIndustry
- Sponsor type
- Industry
- First posted
- Jul 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a Phase 1/2 dose-finding and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV400. The study will enroll patients with relapsed/refractory B-cell malignancies, including large B-cell lymphoma (LBCL).
Conditions
- Lymphoma, B Cell
- Lymphoma Non-Hodgkin
- High Grade B Cell Lymphoma
- Richter Transformation Lymphoma
- Grade 3b Follicular Lymphoma
- Primary Mediastinal B Cell Lymphoma
- Diffuse Large B Cell Lymphoma (DLBCL)
Interventions
UB-VV400Genetic
UB-VV400 is a gene therapy that generates CD22-directed CAR T cells in the body.
Rapamycin (sirolimus)Drug
Rapamycin is a drug approved by the FDA for indications unrelated to cancer.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Percentage of participants with common adverse events (AEs)Time frame: Up to 2 years after UB-VV400 administration
- Phase 2: Overall response rate (ORR)Time frame: Up to 2 years after UB-VV4001 administration
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
City of Hope
Irvine, California · Recruiting
Sarah Cannon Research Institute
Nashville, Tennessee · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.